Kano
Kano Therapeutics is seeking talented individuals to join their team, encouraging applicants to submit their CVs and introduce themselves even if no specific role matches their background. The company harnesses DNA nanotechnology and synthetic biology to design novel gene constructs and expand genome-editing-based therapies through transformational biomaterials. This open application process allows the team to follow up if they identify a potential match.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1-10 employees
Founded
2021
Kano Therapeutics is a genetic medicine company developing circular single-stranded DNA (cssDNA) as a high-fidelity, immune-quiet, and scalable DNA payload platform for cell and gene therapy. Its proprietary KanoDNA technology supports applications including CRISPR-based knock-ins, next-generation gene editing, and non-integrating episomal expression, offering advantages over viral vectors and double-stranded DNA products. Kano manufactures cssDNA via industrial fermentation and partners with therapeutic developers from research through GMP supply.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Kano.
Kano didn’t post a salary, so this is our estimate from similar listings.
3% below the average for this role
Postdoctoral Associate
New York University
Technical Sales Specialist - GWE, APAC
Cepheid
Research Associate
Texas A&M University Health Science Center
Postdoctoral Research Fellow/Research Associate
University of North Carolina at Chapel Hill
Scientist I
Alloy Therapeutics
Advisor, Molecular Biology
Eli Lilly and Company